Results of endoscopic Injection of Total Blood Nucleated Cells for Vesicoureteral Reflux Treatment in adult

short term results of endoscopic Injection of Total Blood Nucleated Cells for Vesicoureteral Reflux Treatment in adult

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016050926038N2

Enrollment

Registered

2016-06-02

Start date

2012-03-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vesicoureteral Reflux. Vesicoureteral-reflux-associated uropathy

Interventions

Endoscopic Injection of Total Blood Nucleated Cells.

Treatment - Drugs

Endoscopic Injection of Total Blood Nucleated Cells

Eligibility

Sex/Gender

Female

Age

18 Years to 35 Years

Inclusion criteria

Inclusion criteria: the inclusion criterias were a diagnosis of VUR by a recent VCUG , age >18years , recurrent pyelonephritis, a clinical history of VUR, have not history of surgical treatment of VUR and consent for participation in study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Vesicoureteral Reflux grade. Timepoint: 3 months after the endoscopic injection. Method of measurement: renal ultrasonography and radiologic VCUG.	—

Secondary

Measure	Time frame
Vesicoureteral reflux grade. Timepoint: 3 months after the injection. Method of measurement: renal ultrasonography and radiologic VCUG.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSalman Soltani

Mashhad University of Medical Siences, Urology Department

soltanis911@mums.ac.ir+98 51 3852 5312

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026